Industry news that matters to you.  Learn more

ValueOptions And Genomind Announce Innovative Study Of Pharmacogenomic Testing For Treating Psychotic Disorders

ValueOptions®, Inc. a health improvement company specializing in mental and emotional well-being and recovery, and Genomind, a personalized medicine company, recently announced an innovative study that uses pharmacogenomic testing to treat patients diagnosed with psychotic disorders, including schizophrenia and bipolar disorder. The study will be conducted at North Shore-LIJ Health System’s Zucker Hillside Hospital, a nationally recognized behavioral health center in Glen Oaks, NY.